CHEMOMAB THERAPEUTICS LTD.
Ownership & governance
Executives 5Directors 6Avg age 59Avg tenure 5.3y
AM
Adi Mor
Chief Executive Officer
Age 45Since 2023-05-31Profile →
+10
Executives5
Board of directors6
AM
Adi Mor→
Director/Board Member
Age 45Since 2011-09-21
ND
Nissim Darvish→
Chairman
Age 61Since 2023-05-31
AM
Alan Moses→
Director/Board Member
Age 78Since 2021-03-15
CN
Claude Nicaise→
Director/Board Member
Age 74Since 2021-03-15
NC
Neil Cohen→
Director/Board Member
Age 62Since 2020-03-31
JQ
Jill Quigley→
Director/Board Member
Age 51Since 2022-06-20
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| OrbiMed Advisors Private Equity | 4.532 % | 235,248 |
| Adar1 Capital Management LLC | 1.541 % | 80,000 |
| Citadel Securities GP LLC | 1.236 % | 64,182 |
| Kestra Private Wealth Services LLC | 1.189 % | 61,710 |
| Ikarian Capital LLC | 0.9977 % | 51,793 |
Catalog · 2026-07-09
Registry officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| Adi Mor | Chief Executive Officer | 2023-05-31 | - |
| David Weiner | Chief Tech/Sci/R&D Officer | 2021-12-02 | - |
| Ilan Vaknin | Chief Tech/Sci/R&D Officer | 2022-08-11 | - |
| Nissim Darvish | Chairman | 2023-05-31 | - |
| Sigal Fattal | Director of Finance/CFO | 2023-05-31 | - |
| Adi Mor | Director/Board Member | 2011-09-21 | - |
| Alan Moses | Director/Board Member | 2021-03-15 | - |
| Claude Nicaise | Director/Board Member | 2021-03-15 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 5Range 5–5Analysts 1
- Strong buy 1
Broker actions14
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | 25 | 2025-08-27 |
| Oppenheimer | Maintained | Outperform | 10 | 2025-05-16 |
| Maxim Group | Maintained | Buy | 7 | 2025-02-20 |
| Oppenheimer | Reiterated | Outperform | 11 | 2024-11-15 |
| Maxim Group | Initiated | Buy | 4 | 2024-05-13 |
| Oppenheimer | Upgrade | Outperform | 6 | 2024-05-06 |
| Oppenheimer | Maintained | Perform | — | 2024-03-08 |
| Roth MKM | Initiated | Buy | 7 | 2023-10-06 |
| Oppenheimer | Downgrade | Perform | — | 2023-06-07 |
| Oppenheimer | Maintained | Outperform | 7 | 2023-04-18 |
| Oppenheimer | Maintained | Outperform | 20 | 2022-03-10 |
| Aegis Capital | Initiated | Buy | 30 | 2021-12-07 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.